Travere Therapeutics (TVTX) Insider Trading & Ownership $17.60 +0.91 (+5.42%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Travere Therapeutics (NASDAQ:TVTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage3.75%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$6.18 M Get TVTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Travere Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TVTX Insider Buying and Selling by Quarter Travere Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/11/2025Christopher R ClineCFOSell48$13.14$630.72 2/12/2025William E RoteSVPSell5,200$23.53$122,356.00 2/11/2025Eric M DubeCEOSell11,375$24.04$273,455.00 2/11/2025Peter HeermaInsiderSell3,074$25.00$76,850.00 2/11/2025Sandra CalvinCAOSell54,244$25.00$1,356,100.00 2/6/2025Roy D BaynesDirectorSell10,000$22.00$220,000.00 2/3/2025Christopher R ClineCFOSell5,192$20.12$104,463.04 2/3/2025Eric M DubeCEOSell50,691$20.21$1,024,465.11 2/3/2025Jula InrigInsiderSell4,207$20.12$84,644.84 2/3/2025Sandra CalvinCAOSell3,348$20.12$67,361.76 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/3/2025William E RoteSVPSell8,951$19.78$177,050.78 1/23/2025Roy D BaynesDirectorSell16,000$20.00$320,000.00 1/22/2025Christopher R ClineCFOSell865$18.94$16,383.10 1/22/2025Eric M DubeCEOSell10,736$19.46$208,922.56 1/22/2025Peter HeermaInsiderSell1,584$18.94$30,000.96 1/22/2025Sandra CalvinCAOSell925$18.94$17,519.50 1/22/2025William E RoteSVPSell2,437$19.46$47,424.02 1/6/2025Jula InrigInsiderSell440$18.76$8,254.40 1/3/2025Jula InrigInsiderSell2,066$19.10$39,460.60 12/26/2024Sandra CalvinCAOSell15,000$17.22$258,300.00 11/25/2024Sandra CalvinCAOSell12,090$18.30$221,247.00 10/4/2024Gary A LyonsDirectorSell40,000$14.73$589,200.00 9/30/2024Jeffrey A MecklerDirectorSell40,000$14.06$562,400.00 9/9/2024Christopher R ClineCFOSell2,490$11.52$28,684.80 9/9/2024Eric M DubeCEOSell21,125$11.52$243,360.00 9/9/2024Jula InrigInsiderSell2,191$11.52$25,240.32 9/9/2024William E RoteSVPSell4,387$11.52$50,538.24 9/4/2024Christopher R ClineCFOSell514$9.51$4,888.14 (Data available from 1/1/2013 forward) TVTX Insider Trading Activity - Frequently Asked Questions Who is on Travere Therapeutics's Insider Roster? The list of insiders at Travere Therapeutics includes Christopher R Cline, Elizabeth E Reed, Eric M Dube, Gary A Lyons, Jeffrey A Meckler, Jula Inrig, Laura Clague, Peter Heerma, Roy D Baynes, Sandra Calvin, Steve Aselage, and William E Rote. Learn more on insiders at TVTX. What percentage of Travere Therapeutics stock is owned by insiders? 3.75% of Travere Therapeutics stock is owned by insiders. Learn more on TVTX's insider holdings. Which Travere Therapeutics insiders have been selling company stock? The following insiders have sold TVTX shares in the last 24 months: Christopher R Cline ($209,988.93), Elizabeth E Reed ($32,162.27), Eric M Dube ($2,052,639.20), Gary A Lyons ($589,200.00), Jeffrey A Meckler ($562,400.00), Jula Inrig ($177,214.28), Peter Heerma ($182,275.19), Roy D Baynes ($540,000.00), Sandra Calvin ($1,960,069.80), and William E Rote ($465,562.13). How much insider selling is happening at Travere Therapeutics? Insiders have sold a total of 390,813 Travere Therapeutics shares in the last 24 months for a total of $6,771,511.80 sold. Travere Therapeutics Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Compensation: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Compensation: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Compensation: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Compensation: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Compensation: $742.37k2 recent tradesMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer 5 recent tradesMs. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business Officer More Insider Trading Tools from MarketBeat Related Companies Sarepta Therapeutics Insider Trading Axsome Therapeutics Insider Trading Nuvalent Insider Trading Verona Pharma Insider Trading Grifols Insider Trading Krystal Biotech Insider Trading ADMA Biologics Insider Trading Cytokinetics Insider Trading Elanco Animal Health Insider Trading Vaxcyte Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market Sentiment This page (NASDAQ:TVTX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredMusk’s real agenda in D.C. In this urgent exposé, you’ll discover… How Elon and Donald Trump are quietly drawing a radical new map of ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TVTX Stock Free TVTX Stock Alerts